Lukas Weiß
Paracelsus Medical University · 115 works · 1,672 citations · h-index 24
Top works
- A modified scoring of the NCCN ‐ IPI is more accurate in the elderly and is improved by albumin and β2‐microglobulin
- Impact of antibiotic treatment on immune-checkpoint blockade efficacy in advanced non-squamous non-small cell lung cancer
- Local and Central Evaluation of HER2 Positivity and Clinical Outcome in Advanced Gastric and Gastroesophageal Cancer—Results from the AGMT GASTRIC-5 Registry
- NCCN-IPI score-independent prognostic potential of pretreatment uric acid levels for clinical outcome of diffuse large B-cell lymphoma patients
- Regulatory T cells predict the time to initial treatment in early stage chronic lymphocytic leukemia
- The CIRCULATE Trial: Circulating Tumor DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II Evaluation (AIO-KRK-0217)
- Independent Prognostic Value of Serum Markers in Diffuse Large B-Cell Lymphoma in the Era of the NCCN-IPI
- Prognostic and Predictive Factors in Advanced Head and Neck Squamous Cell Carcinoma
- Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemia
- Viral infections and their management in patients with chronic lymphocytic leukemia
- A phase 1 dose-escalation study on the safety, tolerability and activity of liposomal curcumin (Lipocurc™) in patients with locally advanced or metastatic cancer
- Baseline Absolute Lymphocyte Count and ECOG Performance Score Are Associated with Survival in Advanced Non-Small Cell Lung Cancer Undergoing PD-1/PD-L1 Blockade
- Liver toxicity during temozolomide chemotherapy caused by Chinese herbs
- The significance of pretreatment anemia in the era of R‐ IPI and NCCN ‐ IPI prognostic risk assessment tools: a dual‐center study in diffuse large B‐cell lymphoma patients
- Clonal evolution in relapsed and refractory diffuse large B-cell lymphoma is characterized by high dynamics of subclones
- Circulating tumor DNA-based decision for adjuvant treatment in colon cancer stage II evaluation: (CIRCULATE-trial) AIO-KRK-0217.
- Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial
- Difference in the Relative Distribution of CD4+ T-cell Subsets in B-CLL With Mutated and Unmutated Immunoglobulin (Ig) VH Genes
- Mimicking the microenvironment in chronic lymphocytic leukaemia – where does the journey go?
- A case of long‐term remission with ofatumumab maintenance therapy in multiply relapsed and rituximab‐refractory chronic lymphocytic leukaemia with deletion 17p